| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.1007/S10549-007-9703-8 |
| P2888 | exact match | https://scigraph.springernature.com/pub.10.1007/s10549-007-9703-8 |
| P932 | PMC publication ID | 2001217 |
| P698 | PubMed publication ID | 17912639 |
| P5875 | ResearchGate publication ID | 5931634 |
| P50 | author | Nadia Harbeck | Q38294539 |
| P2093 | author name string | Renate Haidinger | |
| P2860 | cites work | Duration of letrozole treatment and outcomes in the placebo-controlled NCIC CTG MA.17 extended adjuvant therapy trial | Q57578462 |
| Screening for breast cancer | Q57651645 | ||
| Patient-centered care and breast cancer survivors’ satisfaction with information | Q58461843 | ||
| Effect of a Decision Aid on Knowledge and Treatment Decision Making for Breast Cancer Surgery | Q58854488 | ||
| Supportive care provided by physicians and nurses to women with breast cancer | Q59160573 | ||
| Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial | Q59288489 | ||
| Communication between physicians and older women with localized breast cancer: implications for treatment and patient satisfaction | Q60152847 | ||
| Randomized, controlled trial investigating short-term health-related quality of life with doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in patients with metastatic breast cancer: European Organization f | Q64111915 | ||
| Helping Patients Make Informed Choices: A Randomized Trial of a Decision Aid for Adjuvant Chemotherapy in Lymph Node-Negative Breast Cancer | Q64944748 | ||
| Patients' reactions to completion of adjuvant breast cancer therapy | Q67936270 | ||
| Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors | Q71745902 | ||
| Consumer participation in the development of psychosocial clinical practice guidelines: opinions of women with breast cancer | Q73650103 | ||
| Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate | Q74195354 | ||
| Prevalence of posttraumatic stress disorder in women with breast cancer | Q74537323 | ||
| Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer | Q79422750 | ||
| Sexual problems in younger women after breast cancer surgery | Q79748469 | ||
| Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17 | Q79844543 | ||
| What do patients with prostate or breast cancer want from an Internet site? A qualitative study of information needs | Q79867661 | ||
| Ten-year outcomes in a population-based cohort of node-negative, lymphatic, and vascular invasion-negative early breast cancers without adjuvant systemic therapies | Q80026129 | ||
| The combination of letrozole and trastuzumab as first or second-line biological therapy produces durable responses in a subset of HER2 positive and ER positive advanced breast cancers | Q80081696 | ||
| Hormone receptor status does not affect the clinical benefit of trastuzumab therapy for patients with metastatic breast cancer | Q81151638 | ||
| Neoadjuvant endocrine therapy in breast cancer | Q81361849 | ||
| Factors affecting patients' perceptions of choice regarding adjuvant chemotherapy for breast cancer | Q82847071 | ||
| Estrogen-independent proliferation is present in estrogen-receptor HER2-positive primary breast cancer after neoadjuvant letrozole | Q83930167 | ||
| Addition of drug/s to a chemotherapy regimen for metastatic breast cancer | Q24245443 | ||
| Chemotherapy alone versus endocrine therapy alone for metastatic breast cancer | Q24248696 | ||
| Overdiagnosis and overtreatment of breast cancer: overdiagnosis in randomised controlled trials of breast cancer screening | Q24813875 | ||
| Overdiagnosis and overtreatment of breast cancer: estimates of overdiagnosis from two trials of mammographic screening for breast cancer. | Q25257412 | ||
| Overdiagnosis and overtreatment of breast cancer: rates of ductal carcinoma in situ: a US perspective | Q25257762 | ||
| Gene expression profiling predicts clinical outcome of breast cancer | Q27860732 | ||
| A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer | Q28297827 | ||
| Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials | Q29547513 | ||
| Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis | Q30004190 | ||
| Quality of life among younger women with breast cancer | Q30150819 | ||
| Emerging data on optimal adjuvant endocrine therapy: Breast International Group trial 1-98/MA.17. | Q31036081 | ||
| Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer | Q31960178 | ||
| Depression and anxiety in women with early breast cancer: five year observational cohort study | Q33934898 | ||
| Satisfaction with surgery outcomes and the decision process in a population-based sample of women with breast cancer | Q34337362 | ||
| Integrated modeling of clinical and gene expression information for personalized prediction of disease outcomes | Q34375924 | ||
| Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. | Q34382805 | ||
| Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial | Q34440858 | ||
| Accuracy and self correction of information received from an internet breast cancer list: content analysis | Q34499187 | ||
| Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate | Q34516345 | ||
| A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer | Q34563755 | ||
| Overdiagnosis and overtreatment of breast cancer: is overdiagnosis an issue for radiologists? | Q35012740 | ||
| Overdiagnosis and overtreatment of breast cancer: progression of ductal carcinoma in situ: the pathological perspective | Q35012751 | ||
| Understanding the breast cancer experience of women: a qualitative study of African American, Asian American, Latina and Caucasian cancer survivors | Q35103757 | ||
| Review of determinants of patients' preferences for adjuvant therapy in cancer. | Q35850860 | ||
| Risk of ischemic stroke with tamoxifen treatment for breast cancer: a meta-analysis | Q35914872 | ||
| Care of the breast cancer survivor: increased survival rates present a new set of challenges | Q35930942 | ||
| American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. | Q35951294 | ||
| Long-term risk of breast cancer recurrence: the need for extended adjuvant therapy | Q36138483 | ||
| Informational and emotional needs of long-term survivors of breast cancer | Q36228130 | ||
| Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. | Q36251476 | ||
| Survivorship and complications of treatment in breast cancer. | Q36258977 | ||
| Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole Trial | Q46595222 | ||
| What survival benefits do premenopausal patients with early breast cancer need to make endocrine therapy worthwhile? | Q46626941 | ||
| Patients' preferences for adjuvant chemotherapy in early breast cancer: what makes AC and CMF worthwhile now? | Q46673536 | ||
| Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. | Q46689583 | ||
| Assessment of quality of life in MA.17: a randomized, placebo-controlled trial of letrozole after 5 years of tamoxifen in postmenopausal women | Q46699329 | ||
| Distress, coping, and social support among rural women recently diagnosed with primary breast cancer | Q46792802 | ||
| Menopausal symptoms in women treated for breast cancer: the prevalence and severity of symptoms and their perceived effects on quality of life. | Q46905063 | ||
| Caution: Vaginal estradiol appears to be contraindicated in postmenopausal women on adjuvant aromatase inhibitors | Q46916923 | ||
| Annual hazard rates of recurrence for breast cancer after primary therapy. | Q50616854 | ||
| Effects of aromatase inhibition on sexual function and well-being in postmenopausal women treated with testosterone: a randomized, placebo-controlled trial. | Q50941124 | ||
| Self-blame and distress among women with newly diagnosed breast cancer. | Q50961010 | ||
| Psychosocial impact of newly diagnosed advanced breast cancer. | Q50991652 | ||
| Fears about breast cancer recurrence:. | Q51053357 | ||
| Early psychological adjustment in breast cancer patients: a prospective study. | Q51951706 | ||
| Fatigue and menopausal symptoms in women with breast cancer undergoing hormonal cancer treatment. | Q53255325 | ||
| Predictors of quality of life in newly diagnosed melanoma and breast cancer patients. | Q53301946 | ||
| Letrozole, a new oral aromatase inhibitor: randomised trial comparing 2.5 mg daily, 0.5 mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer. Letrozole International Trial Group (AR/BC3). | Q53352963 | ||
| Acceptance of adjuvant therapy and quality of life issues | Q36260380 | ||
| Biomolecular markers of breast cancer | Q36348257 | ||
| Managing patients on endocrine therapy: focus on quality-of-life issues | Q36391478 | ||
| Implementation of a prechemotherapy educational intervention for women newly diagnosed with breast cancer | Q36398272 | ||
| Adherence to tamoxifen over the five-year course | Q36422926 | ||
| Exemestane after tamoxifen as adjuvant hormonal therapy in postmenopausal women with breast cancer: effects on body composition and lipids | Q36612045 | ||
| Randomised controlled trial of mammographic screening in women from age 40: predicted mortality based on surrogate outcome measures | Q36616394 | ||
| Chemotherapy for advanced breast cancer: what influences oncologists' decision-making? | Q36623000 | ||
| Multicenter randomized phase III trial of epirubicin plus paclitaxel vs epirubicin followed by paclitaxel in metastatic breast cancer patients: focus on cardiac safety | Q36625974 | ||
| Decreased rates of advanced breast cancer due to mammography screening in The Netherlands | Q36695572 | ||
| Women's preferences for discussion of prognosis in early breast cancer | Q37331243 | ||
| The decision-making experience among women diagnosed with stage I and II breast cancer | Q38574237 | ||
| Managing menopausal symptoms in breast cancer survivors: results of a randomized controlled trial | Q39428803 | ||
| Gene-expression profiling and the future of adjuvant therapy | Q40374729 | ||
| Giving patients a choice improves quality of life: a multi-centre, investigator-blind, randomised, crossover study comparing letrozole with anastrozole. | Q40474967 | ||
| Restoration of estrogen responsiveness by blocking the HER-2/neu pathway. | Q40698177 | ||
| Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. | Q40727923 | ||
| Predictors of sexual health in women after a breast cancer diagnosis | Q40789896 | ||
| Intracellular aromatase and its relevance to the pharmacological efficacy of aromatase inhibitors | Q40802154 | ||
| An open randomised trial of second-line endocrine therapy in advanced breast cancer. comparison of the aromatase inhibitors letrozole and anastrozole | Q42610796 | ||
| Education about genetic testing for breast cancer susceptibility: patient preferences for a computer program or genetic counselor | Q42659899 | ||
| A decision aid to assist in adjuvant therapy choices for breast cancer | Q42681645 | ||
| Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial | Q43595450 | ||
| Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1. | Q43646734 | ||
| Letrozole as primary medical therapy for locally advanced and large operable breast cancer. | Q43711061 | ||
| Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study | Q43873472 | ||
| Evaluation of an internet support group for women with primary breast cancer | Q44009388 | ||
| Distinct breast cancer incidence and prognostic patterns in the NCI's SEER program: suggesting a possible link between etiology and outcome | Q44039566 | ||
| Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial | Q44045676 | ||
| Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (n = 3424). | Q44106077 | ||
| Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group | Q44459245 | ||
| A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer | Q44613177 | ||
| Letrozole inhibits tumor proliferation more effectively than tamoxifen independent of HER1/2 expression status | Q44618254 | ||
| A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer | Q44795543 | ||
| Her2/neu expression predicts the response to antiaromatase neoadjuvant therapy in primary breast cancer: subgroup analysis from celecoxib antiaromatase neoadjuvant trial | Q44989590 | ||
| Superiority of letrozole to tamoxifen in the first-line treatment of advanced breast cancer: evidence from metastatic subgroups and a test of functional ability | Q45101561 | ||
| Breast cancer in older women: quality of life and psychosocial adjustment in the 15 months after diagnosis. | Q45188674 | ||
| Evaluation of a breast cancer patient information and support program. | Q46002134 | ||
| Quality of life at the end of primary treatment of breast cancer: first results from the moving beyond cancer randomized trial | Q46085538 | ||
| The influence of letrozole on serum lipid concentrations in postmenopausal women with primary breast cancer who have completed 5 years of adjuvant tamoxifen (NCIC CTG MA.17L). | Q46427619 | ||
| Quality-adjusted survival in a crossover trial of letrozole versus tamoxifen in postmenopausal women with advanced breast cancer | Q46537570 | ||
| A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer | Q46586619 | ||
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | nitrile | Q333936 |
| tamoxifen | Q412178 | ||
| breast neoplasm | Q23929670 | ||
| triazoles | Q903341 | ||
| selective estrogen-receptor modulators | Q903917 | ||
| local neoplasm recurrence | Q54945651 | ||
| hormone-dependent neoplasms | Q71959899 | ||
| hormonal antineoplastic agent | Q50430266 | ||
| P304 | page(s) | 91-103 | |
| P577 | publication date | 2007-10-03 | |
| P1433 | published in | Breast Cancer Research and Treatment | Q326085 |
| P1476 | title | The patient experience | |
| P478 | volume | 105 Suppl 1 |
| Q44027133 | Aquatic exercise in a chest-high pool for hormone therapy-induced arthralgia in breast cancer survivors: a pragmatic controlled trial. |
| Q35095617 | Integrating Palliative Medicine into Comprehensive Breast Cancer Therapy - a Pilot Project |
| Q43627047 | Patient and physician perceptions on continuing aromatase inhibitors beyond the 5-year mark |
| Q37851017 | Topical preparations for pain relief: efficacy and patient adherence |
Search more.